- Open Access
miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies
Molecular Cancervolume 14, Article number: 185 (2015)
BCL-xL is an anti-apoptotic BCL-2 family protein that inhibits apoptosis and is overexpressed in many cancers. We have reported that acquired resistance to the BCL-2 inhibitor ABT-199 (venetoclax) is associated with increased BCL-xL expression. Yet, how BCL-xL mediates chemoresistance in hematopoietic malignancies is not clear. This finding may help in design of new strategies for therapeutic intervention to overcome acquired chemoresistance mediated by BCL-xL.
We now show that the increased BCL-xL expression was inversely correlated with that of miR-377 in ABT-199-resistant cells. This finding was also extended to a panel of B-cell lymphoid lines and primary chronic lymphocytic leukemia (CLL) cells. miR-377 suppressed BCL-xL expression by recognizing two binding sites in the BCL-xL 3’-UTR. Mutation of these two miR-377 consensus-binding sites completely abolished its regulatory effect. Expression of a miR-377 mimic downregulated BCL-xL protein expression and significantly increased apoptotic cell death. Expression of a miR-377 inhibitor restored BCL-xL protein expression and limited cell death caused by the hypomethylating agent 5-azacytidine. Thus, miR-377-dependent BCL-xL regulation drives acquired therapeutic resistance to ABT-199. We further show that CLL patients who received a diverse array of chemotherapy regimens also had significantly higher BCL-xL and lower miR377 expression, indicating that exposure to chemotherapy might trigger transcriptional silencing of miR-377, which results in high levels of BCL-xL. Importantly, CLL patients with high BCL-xL/low miR-377 expression had an advanced tumor stage. Moreover, the high BCL-xL expression correlated with short treatment-free survival in 76 CLL patients. miR-377 is located at 14q32 in the DLK1-DIO3 region, which encodes the largest tumor suppressor miRNA cluster in humans. Examination of five additional 14q32 miRNAs revealed that the majority were significantly down-regulated in most CLL patients as well as in ABT-199-resistant cell lines. Remarkably, four of these miRNAs had significantly decreased expression in chemotherapy-treated CLL patients as compared to those untreated. These findings indicate a reduced expression of multiple miRNAs that may reflect a global silencing of this miRNA cluster in therapy-resistant lymphoid cells.
These findings reveal a novel mechanism by which down-regulation of miR-377 increases BCL-xL expression, promoting chemotherapy resistance in B-cell lymphoid malignancies.
The BCL-2 family proteins regulate apoptosis primarily on the mitochondrial outer membrane through the intrinsic apoptotic pathway [1, 2]. These proteins are divided into three classes based on their BCL-2 homology (BH) domains (BH1-BH4) and function : anti-apoptotic [BCL-2, BCL-xL, BCL-W, MCL-1, BCL2A1 (BFL-1, A1), and BCL-B], pro-apoptotic multi-domain effectors (BAX and BAK), and BH3-only proteins (e.g. BIM, PUMA, and NOXA). Inhibition of apoptosis is accomplished by sequestering pro-apoptotic proteins and thus preventing mitochondrial outer membrane permeabilization .
Blocked apoptosis is a hallmark of treatment-resistant cancers and thus it suggests that BCL-2 family members have potential as clinical biomarkers [1, 5]. In fact, several studies have linked BCL-2 family expression and response to chemotherapy in different types of cancers. It has been reported that patients with cancers highly “primed” to cross the apoptotic threshold exhibit superior clinical responses to chemotherapy . For chronic lymphocytic leukemia (CLL), high BCL-2 and MCL-1 expression levels have been reported to mediate resistance to chlorambucil, fludarabine, and rituximab [7–9]. Although numerous studies have focused on the role of BCL-2 or MCL-1 in CLL, the role of other anti-apoptotic proteins and their contribution to clinical outcome is not clearly defined. Most importantly, pharmacologic inhibitors of BCL-2 family proteins are poised for widespread clinical use, so there is an immediate need for development of markers that can rationally direct and better personalize the use of these agents in the clinic . We have developed an anti-apoptotic BCL-2 family expression index that can predict the response of hematological cells, including CLL, as well as solid tumor malignancies, to the rationally designed BCL-2 family inhibitor, ABT-737/ABT-263 (navitoclax) . ABT-199 (venetoclax), a second-generation, rationally designed inhibitor that was re-engineered to bind selectively to BCL-2, shows anti-tumor activity in primary tumor cells and xenograft models [12, 13]. Phase I clinical trials with ABT-199 have had high patient response rates that include many complete responses .
Lymphoid malignancies, most commonly derived from B-cell precursors include more than 40 distinct tumor types, varying widely in phenotype and clinical behavior . CLL, the most common leukemia in the Western world , is characterized by an expansion of small mature B cells in blood, lymph nodes, and bone marrow. Its heterogeneous clinical course [17, 18] has led to a search for markers that can predict disease progression to allow better management of the disease. Mutational status of the immunoglobulin heavy chain variable (IGHV) region dichotomizes CLL patients into two risk categories: those with unmutated IGHV have an unfavorable prognosis, whereas patients with mutated IGHV tend to have a more favorable prognosis. ZAP70 and CD38 expression can serve as a surrogate for an unmutated IGHV gene, thus functioning as prognostic markers [19, 20]. Despite of their clinical value, there are technical difficulties that preclude optimal use of these markers, such as standardization and reproducibility [21, 22]. In addition, p53 deletion is a well-established marker of shorter survival and chemotherapy resistance ; however, it is present in only a small percentage of patients with CLL at the initial diagnosis [24, 25]. Overall, existing established prognostic markers fail to predict clinical outcome in a considerable number of patients with CLL . Moreover, it is difficult to integrate the results of these various markers to assess the overall risk in an individual patient . Thus, developing additional markers for CLL is of considerable interest as they may indicate inherent biologic differences that may be amenable to targeted therapeutic intervention.
MicroRNAs (miRs) are small non-coding regulatory RNAs that bind to a specific target mRNA through a sequence that is complementary primarily to the 3’-UTR of the target mRNA. They have roles in many underlying cancer processes, including proliferation, apoptosis, and invasion [26, 27]. miRNAs are very stable and are found in body fluids such as plasma, serum, and urine, therefore cancer-specific miRNAs could potentially be used as a tumor molecular signature to track and predict cancer progression and to guide treatment .
Here, we report that high BCL-xL expression inversely correlated with decreased levels of a newly identified miR-377. Mutational and functional analyses validated BCL-xL as a direct target of miR-377. Moreover, we show that BCL-xL/miR-377 regulation in diffuse large B-cell lymphoma (DLBCL) cells drives acquired therapeutic resistance to ABT-199 and is associated with advanced tumor stage in CLL patients. Collectively, these data support a model in which co-regulation of BCL-xL and miR-377 mediates a novel mechanism of acquired therapeutic resistance in B-cell lymphoid malignancies.
High BCL-xL expression mediates chemotherapy resistance to ABT-199 in B-cell lymphoid malignancies
ABT-199 is a rationally designed selective BCL-2 inhibitor that has shown promising results in clinical trials, so understanding the mechanism of acquired resistance to it is important. To this end, we generated ABT-199-resistant (ABT-199R) cell lines from initially sensitive SU-DHL-6 and OCl-LY19 DLBCL cells derived from germinal center B cells (GCB). These GCB-DLBCL cell lines with initial low expression of BCL-xL are ideally suited for studying the correlation of high BCL-xL and acquired resistance to chemotherapy . Using a chronic exposure protocol we have described previously , we show that SU-DHL-6-199R (S6-R) and OCL-LY-19-199R (OC-R) cells were 4-and 3-fold more resistant, respectively to ABT-199  than parental cells. BCL-xL mRNA levels, as determined by RT-PCR, were more than three-fold higher in ABT-199R OC-R and S6-R as compared to the parental OC and S6 cells (Fig. 1a). As we have previously shown that acquired resistance to ABT-737 occurs via elevated MCL-1 levels that sequester the pro-apoptotic protein BIM , leading to a block of apoptosis in response to ABT-737, we examined whether BCL-xL directly mediates ABT-199 resistance by sequestering BIM. Immunoprecipitation of BCL-xL and examination of BIM levels revealed that more BCL-xL-interactive BIM was present in the S6-R cells as compared with the parental cells , indicating its functional importance in regulating apoptosis resistance.
BCL-xL is regulated at the post-transcriptional level by miR-377
To address the molecular mechanism that mediates high BCL-xL RNA levels in resistant cells, we first determined whether BCL-xL is regulated at the transcriptional level by examining activation of the known BCL-xL regulatory transcription factors, STAT3 and NF-κB . As these transcription factors were not activated in our ABT-199R cells (data not shown), it is less likely that the high BCL-xL expression observed is a result of transcriptional regulation.
We next addressed the possibility that altered BCL-xL RNA stability is controlled by a miRNA. Using target prediction software (microRNA.org) to identify miRNAs that have a putative BCL-xL target, we found that miR-377 had the highest score rank of all candidates (Table 1). We decided to focus on miR-377 for two reasons: (i) the prediction analysis identified two complementary sequences in the 3’-UTR of BCL-xL mRNA that miR-377 is likely to base-pair with (Additional file 1: Figure S1A), thus suggesting that it is a potential target, and (ii) miR-377 is located at 14q32, the deleted chromosome 14 region that has been described in B-cell lymphomas , suggesting that miR-377 may function as a tumor suppresser gene. To test whether miR-377 mediates BCL-xL expression, we first examined whether its expression was associated with that of miR-377. Indeed, expression of miR-377 inversely correlated with that of BCL-xL in ABT-199R cells (Fig. 1b).
BCL-xL is a direct target of miR-377
Bioinformatics analysis of the BCL-xL 3’-UTR using RNAhybrid and miRbase predicted two potential binding sites for miR-377 at positions 1238 and 1412 (Additional file 1: Figure S1A). To examine whether BCL-xL is a direct target of miR-377, we monitored its expression using a 3’-UTR luciferase reporter assay to examine whether the observed reduction in BCL-xL expression during miR-377 up-regulation is a result of a direct targeting of its 3’-UTR by miR-377. We thus cloned a region of BCL-xL 3’-UTR (1107 to 1491 nucleotides) containing both of the predicted binding sites downstream of the stop codon of the firefly luciferase open reading frame (Fig. 1c). We also generated mutants (MUT) of miR-377 target sites (Fig. 1d). In the C1 and C2 3’-UTR mutants, seven nucleotides 1238–1244 and 1412–1418, respectively of the target site were mutated to disrupt miR-377 interaction in the predicted seed region (Fig. 1e). In the third C3 mutant (double 3’-UTR mutant), we combined both upstream and downstream miR-377 seed region mutations in order to simultaneously disrupt the miR-377/BCLxL interaction at both sites (Fig. 1e). Each of these constructs was co-transfected with either a miR-377 or a negative control mimic in CHO-K1 cells, with renilla luciferase used as an internal control, and the luciferase activity was measured after 48 h. Ectopic miR-377 mimic expression down-regulated the wild-type (WT) 3’-UTR-associated luciferase activity by ~ 46 % as compared with the negative control mimic (Fig. 1f). Cells transfected with C1- and C2 3’-UTR luciferase reporter and the miR-377 mimic showed reversal of this repression in reporter activity by 22 and 36 %, respectively (Fig. 1f). Remarkably, in cells transfected with the C3 double mutant 3’-UTR luciferase reporter, miR-377 mimic expression was unable to suppress luciferase activity at all. These cells exhibited a complete reversal of luciferase activity, which indicates a direct binding of miR-377 to the predicted target sites in the BCL-xL 3’-UTR (Fig. 1f). Taken together, these data demonstrate that the predicted target sites in the BCL-xL 3’-UTR are authentic and specific binding sites for miR-377 and, therefore, provide support to our discovery of BCL-xL as a direct target of miR-377.
Using both mFold and Nupack RNA folding algorithms, we analyzed the contextual/local secondary structures around the predicted miRNA target site in the short and full length 3’-UTR of BCL-xL transcript to eliminate the possibility that different secondary structures may influence miRNA binding. Thus, the contextual structure between the secondary structure of the short and the full-length BCL-xL 3’-UTRs, as predicted by mFold RNA folding algorithm, appears to be very similar as both contain six varied size bulges and an almost similar number of helices (Additional file 1: Figure S1B). Therefore, irrespective of the size of the 3’-UTR fragment utilized for target validation assay, our analyses support our above findings that BCL-xL is a target of miR-377. As a second independent approach to experimentally confirm that miR-377 is involved in the regulation of BCL-xL, a gain-of-function experiment indicated that adding miR-377 mimics at a concentration as low as 50 nM led to a substantial decrease in endogenous BCL-xL protein expression, thus confirming that miR-377 is a direct target of BCL-xL (Fig. 1g).
miR-377-dependent BCL-xL regulation drives resistance to ABT-199
To address the molecular mechanism that mediates down regulation of miR-377 in ABT-199- resistant cell lines, we hypothesized that miR-377 might be epigenetically silenced, as several studies reported that miRs are regulated by methylation [34–36]. Indeed, treatment of ABT-199R cells with the DNA-hypomethylating agent 5-Aza-2′-deoxycytidine (5-Aza) for 72 h led to re-expression of miR-377, which was also associated with a decrease in BCL-xL expression (Fig. 2a and b), indicating a tight regulation at the molecular level between BCL-xL and miR-377 expression. Interestingly, ABT-199R cells were highly sensitive to 5-Aza as compared to parental cells (Fig. 2c), indicating that targeting BCL-xL by re-expression of miR-377 can significantly increase cell death (P < 0.005) of ABT-199R cells. Moreover, targeting BCL-xL in S6-R cells by transfecting either miR-377 mimics or siBCL-xL led to decrease in BCL-xL expression and significant increase (P < 0.005) in cell death (Fig. 2d and e). Importantly, expression of BCL-xL significantly increased cell viability (P = 0.017) in miR-377 mimic-treated S6-R cells (Fig. 2f and g). These results indicate that BCL-xL expression can rescue cell viability after treatment with the miR-377 mimic.
To demonstrate that re-expression of miR-377 by 5-Aza impacts on BCL-xL expression, we sought to inhibit miR-377 function with a miR-377 inhibitor consisting in a single-strand reverse complement to the mature miR-377 strand, which is used for preventing its binding to endogenous targets. We therefore treated S6-R cells with 5-Aza for 24 h and then transfected them with the miR-377 inhibitor and then assessed cell viability and BCL-xL expression after 48 h (72 h total time of treatment). Our data indicate that targeting miR-377 led to a substantial blunting of the effect of 5-Aza, as indicated by a significant decrease in cell death (P = 0.04) and BCL-xL expression (Fig. 2h and i).
High BCL-xL expression correlates with low miR-377 expression in B-cell lymphoid malignancies, including CLL patients
We next addressed the generality of the association of BCL-xL and miR-377 expression in a panel of lymphoid B-cell lines. Remarkably, high BCL-xL expression inversely correlated with low miR-377 expression in the seven cell lines examined (Fig. 3a). Importantly, expression of miR-377 inversely correlated (P < 0.001, r = −0.82) with that of BCL-xL in primary CLL patient samples (Fig. 3b and c). Interestingly, we also found that cell lines that have high BCL-xL and low miR-377 expressions are highly resistant to ABT-199 (Additional file 2: Figure S2). In addition, two out of the three cell lines that have high BCL-xL and low miR-377 expression were established from relapsed/higher tumor stage patients.
Next, we wanted to test whether expression of BCL-xL and miR-377 correlate with the severity of the clinical course in CLL patients. Indeed, CLL patients with high BCL-xL/low miR-377 have more advanced tumor stage than CLL patients with low BCL-xL/high miR-377 expression (Fig. 3d). Importantly, CLL patients that were previously treated with a wide range of chemotherapeutic regimens had decreased miR-377 expression as compared to untreated CLL patients (Fig. 3e), indicating that exposure to chemotherapy might trigger transcriptional silencing of miR-377, which results in high levels of BCL-xL. These finding may reveal a new mechanism of resistance, in which transcriptional silencing of miR-377, which results in high levels of BCL-xL promotes resistance to chemotherapy.
miRNAs in the 14q32 cluster region are down-regulated in therapy-resistant cells
It has been previously shown that miR-377 is located at 14q32.31. This region on the long arm of chromosome 14 encodes one of the largest miRNA clusters in humans and is classified into two adjacent miRNA clusters:14q32.31 and 14q32.32 . Therefore, we wanted to test whether the reduced expression of miR-377 is unique or reflects a broader silencing of the mIRs located in these two adjacent clusters. To test this, we randomly selected five additional mIRs located in these two clusters: miR-127, miR-136, miR-154, miR-337, and miR-379 to examine their expression in our CLL patients. Our data indicate that majority of these miRs were significantly down-regulated (P < 0.001) in most CLL patients (Fig. 4a). Interestingly, we found that four out these five mIRs had significantly decreased expression in chemothrapy-treated CLL patients as compared to untreated CLL patients (Fig. 4b to f). These findings are consistent with our miR-377 data, which suggest that exposure to chemotherapy might trigger transcriptional silencing of the miRs located in the 14q32 region. Similar differences in the expression of these mIRs were seen in the ABT-199R cell lines compared to parental S6 and OC cells (Fig. 4g).
Previously treated CLL patients show higher BCL-xL expression
The current standard of care for CLL patients involves sequential cycles of chemotherapy - most often purine analogs or alkylating agents - in combination with an anti-CD20 monoclonal antibody. As almost all CLL patients will eventually relapse, development of acquired resistance to chemotherapy is a significant clinical problem. As 31 of our 76 patients had received a diverse array of chemotherapy regimens, including fludarabine, rituximab, bendamustine, chlorambucil, prednisone, and alemtuzumab, we compared the expression of anti-apoptotic BCL-2 family genes in untreated compared to previously treated patients (Fig. 5). Among all the anti-apoptotic BCL-2 family genes tested, only BCL-xL expression was significantly higher (P = 0.007) in CLL patients who received chemotherapy as compared to those who were never treated (Fig. 5a). This result indicates that regardless of the type of therapy used, BCL-xL might confer resistance to conventional cytotoxic chemotherapy.
High BCL-xL expression is associated with shorter treatment-free survival in CLL patients
Baseline characteristics of the 76 patients with CLL studied are summarized in Table 2. To further investigate whether expression of anti-apoptotic genes, including BCL-xL, contribute to treatment free survival in CLL patients, RT-PCR was used to assess expression of the anti-apoptotic, BCL-2, MCL-1, BCL-xL, BFL-1, BCL-W, and BCL-B and pro-apoptotic, BIM, PUMA, and NOXA genes. Correlations of the expression of each of these genes with time from diagnosis to start of treatment, i.e., treatment-free survival (Fig. 6, Additional file 3: Figure S3) were examined for significance. We also examined the combined expression of all anti-apoptotic and pro-apoptotic BCL-2 family members and ratios of these (data not shown). Only BCL-xL expression emerged as being significantly correlated with treatment-free survival (P = 0.002, Fig. 6a). We next assessed the correlation of common CLL prognostic markers p53, ZAP70, and CD38 with treatment-free survival. Patients with p53 (17p) deletion showed very strong correlation with treatment-free survival, whereas ZAP70 and CD38 failed to indicate such correlation (Fig. 7a, c, and e). In contrast, Jonckheere-Terpstra testing showed no significant correlation trend between BCL-xL expression and increasing Rai stage, ZAP70-positive/negative, CD38-positive/negative, p53 deletion (17p)/normal status (Additional file 4: Figure S4), or commonly detected chromosomal abnormalities (Table 2), thus indicating that BCL-xL expression is independent of known CLL prognostic markers.
BCL-xL expression identifies CLL patients at high risk for shorter treatment-free survival time within the negative-prognostic marker groups
Some patients in the ZAP70-negative, CD38-negative, and normal/unknown p53 (17p) status categories also experienced rapid progression and aggressive disease (Fig. 7a, c, and e). BCL-xL expression was able to identify patients with high risk within these favorable CLL categories. Remarkably, BCL-xL levels could discriminate between patients at high risk who had CD38-negative (P = 0.010), ZAP70-negative (P = 0.019), or normal/unknown p53 (17p) status (P = 0.047), suggesting its potential clinical value (Fig. 7b, d, and f).
CLL undergoes transformation (known as the Richter syndrome), to more aggressive lymphoma, most commonly DLBCL . In our GCB-DLBCL chemotherapeutic resistance model, chronic exposure to ABT-199 up-regulates BCL-xL expression, which is responsible for mediating chemotherapeutic resistance to ABT-199 . In search of the molecular mechanism that mediates high BCL-xL expression, we identified miR-377, expression of which was inversely correlated with that of BCL-xL. In our ABT-199 resistance model, we found that the high BCL-xL expression was due to down-regulation of miR-377, an observation similar to what we found in our CLL patients and a panel of lymphoid B-cell lines. We demonstrate that BCL-xL is a direct target of miR-377 by three independent approaches: (i) a luciferase reporter assay, (ii) miR-377 expression modulation both by a mimic and an inhibitor and (iii) over expression of BCL-xL. While little is known about the molecular function of miR-377, in a comprehensive study using integrative genomic approaches, miR-377, among other miRNAs, was found to correlate with advanced tumor stage in solid tumors [39, 40]. Here, we provide evidence for a tight regulation between miR-377 expression and up-regulation of BCL-xL. Based on these data, we propose a novel mechanism by which lymphoid malignant cells regulate BCL-xL and miR-377 expression in order to promote acquired resistance to chemotherapy. Interestingly, BCL-xL is one of the most frequently amplified oncogenes found in solid tumors . Here we identify a novel, miR-377-dependent regulation as an alternative mechanism for BCL-xL expression in leukemic cells.
miR-377 is located on chromosome 14q, with deletion of this site indicating its potential role as a tumor suppressor. 14q deletions are also associated with trisomy 12, a hallmark of CLL . As the frequency of the 14q deletion is relatively low in hematopoietic malignancies, including CLL , it is not likely to provide a common therapeutic resistance mechanism. Interestingly, there is a growing interest in the 14q32 chromosomal region because ~ 53 miRNAs are embedded in two adjacent clusters (14q32.31 and 14q32.32); those span more than 200 kb, which were found to be deregulated in various human diseases, including various cancers, both hematologic, such as acute promyelocytic leukemia  and of epithelial origin, such as melanoma . These reports support our findings that demethylating agents can restore expression of these miRNAs, including miR-377.
Our ABT-199R model suggests that an alternative, transcriptional silencing mechanism is responsible for the low levels of miR-377 that develop after chronic exposure to ABT-199. Our preliminary experiments using bisulfate genomic sequencing and methylation-specific PCR could not identify differentially methylated regions. Future experiments are needed to delineate how methylation regulates expression of miR-377 and other miRNAs in the 14q32 cluster. Nevertheless, the epigenetic modification of miRNA expression by methylation is well documented. Many miRNAs, including miR-377, are up-regulated following treatment with 5-Aza, a hypomethylating agent approved for use in myeloid, but not lymphoid malignancies [36, 39, 45]. Treatment with 5-Aza led to re-expression of miR-377 leading to decreased BCL-xL expression. Interestingly, unlike parental cells, we found that ABT-199R cells were highly sensitive to 5-Aza. By modulating miR-377 expression with both a mimic and an inhibitor, along with re-expression of BCL-xL, we show that targeting BCL-xL by 5-Aza is a promising approach to overcome ABT-199 resistance. As several hypomethylating agents are currently in clinical use [45, 46], this possibility could be quickly tested in clinical trials.
We show that CLL patients previously treated with a variety of chemotherapeutic regimens had higher BCL-xL and lower miR-377 expression as compared to untreated patients. Moreover, CLL patients with high BCL-xL/low miR-377 expression also have a more advanced tumor stage. These clinically relevant data along with our ABT-199R model suggest that BCL-xL might be critical for conferring general chemotherapy resistance. In support of our findings, other in vitro studies also support a role for BCL-xL in promoting chemotherapy resistance. Thus, chemotherapeutic resistance to a group of compounds that repress MCL-1 expression has been linked to high BCL-xL mRNA expression . This finding indicates that a patient-selection strategy for development of any MCL-1 inhibitor should focus on patients with low BCL-xL expression. Moreover, resistance to 122 standard chemotherapy agents correlated with high BCL-xL expression in the NCI 60 cell line panel .
Although the role of BCL-2 and MCL-1 in the molecular pathogenesis of CLL has been extensively studied, less is known about the role of the other anti-apoptotic BCL-2 family members. Here, we have applied a highly sensitive and quantitative assay to examine the clinical value of expression for all anti-apoptotic BCL-2 family genes. Out of all these gene expression analyses, for individual or different combinations of these genes, only BCL-xL expression had clinically relevant predictive value. In our patient cohort, BCL-2 and MCL-1 levels did not discriminate between those at risk for short treatment free survival and those who were not, consistent with previous reports [8, 49].
In contrast to p53 (17p) deletions, ZAP70 and CD38 did not show significant correlations with treatment free survival in our patient population. Reports conflict on the significance of ZAP70 and CD38 in predicting clinical outcome in CLL, likely because of the lack of a standardized method for determining what constitutes positive and negative test results [21, 22, 50]. Interestingly, we found that BCL-xL expression levels could identify patients at high risk who were negative for ZAP70 or CD38, suggesting the possibility that it is a more robust and/or independent indicator of clinical outcome. While p53 deletions/mutations generally indicate aggressive disease with poor prognosis, the majority of CLL patients, which do not have this abnormality, remain heterogeneous. BCL-xL expression levels were able to further stratify this group in terms of time to requiring treatment, indicating that BCL-xL may also be useful in this context. Our findings that BCL-xL has prognostic value are not limited to CLL. Similarly, it was reported that high BCL-xL expression correlated with short overall survival in follicular lymphoma . As a further support for the role of BCL-xL in a wide range of B lymphoid malignancies, the clinical outcome of GCB-DLBCL patients is better than of those with non-germinal center-DLBCL, likely also due to the fact that GCB-DLBCL cells have significantly lower BCL-xL expression [29, 52].
Our study provides new insights into the role of BCL-xL/miR-377 regulation in chemotherapy resistance in B-cell lymphoid malignancies. As anti-apoptotic BCL-2 family protein inhibitors have shown promising results in clinical trials, our findings underscore the importance of determining expression of the anti-apoptotic BCL-2 family genes, not only for choosing the appropriate targeted therapy and chemotherapy combination for each patient, but also as a means of monitoring the expression of these genes during post-chemotherapy follow-up visits.
Cell lines and reagents
Human lymphoid cell lines SU-DHL-6, OCL-LY-19, Nalm-6, Reh, and IM-9 were obtained from ATCC; Mec-1 and Mec-2 were a gift from Dr Yogen Saunthararajah (Cleveland Clinic). All cell lines were cultured in RPMI-1640 medium supplemented with 10 % fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), and antibiotic-antimycotic (Gibco, Life Technologies, Gaithersburg, MD). Cell lines were routinely screened for mycoplasma, variations in growth rates, changes in morphological characteristics, and their response to stress with Annexin V FITC-PI staining; their passage number did not exceed 20. The development of DLBCL cell lines with acquired resistance to ABT-199 (ABT-199R) was previously described . The ABT199-R cells were routinely tested for resistance to ABT-199 and cultured without drug for 72 h before they were used in experiments.
The wild-type (WT)-3’-UTR reporter plasmid was constructed by cloning a 384-base pair fragment of the BCL-xL 3’-UTR spanning the predicted target site for miR-377 downstream of the firefly luciferase coding region in the pMIR-REPORT vector (Ambion, Austin, TX). Site-directed mutagenesis of the putative target sites for miR-377 in the WT-3’-UTR construct was carried out to generate the mutant MUT-3’-UTR constructs. Nucleotide sequences of the constructs were confirmed by DNA sequencing. Luciferase assays were performed as previously described . CHO-K1 (30,000 cells/well) placed in 24-well plates, 1 day later were co-transfected using Lipofectamine 2000 (Invitrogen), with 100 ng WT-3’-UTR or MUT-3’-UTR firefly luciferase reporter constructs, 0.5 ng renilla luciferase reporter plasmid (Promega, Madison, WI) and either miR-377 or negative control (NC) mimics (10 nM). Cell lysates were assayed for firefly and renilla luciferase activities 48 h after transfection using the dual-luciferase reporter assay system (Promega) and a Victor3 multilabel plate reader (PerkinElmer). Renilla luciferase activity served as a control for transfection efficiency. Data are shown as the ratio of firefly luciferase activity to renilla luciferase activity. All experiments were performed at least three times in triplicate.
Transfections to modulate miR-377 and BCL-xL function
The miR-377 mimic sequence 5’-AUCACACAAAGGCAACUUUUGU-3’ and a Non-Target (negative control) were purchased from Qiagen. They were transfected using HiPerFect transfection reagent (Qiagen, Germantown, MD) in 293 T cells according to manufacturer’s protocol. The effect of the miR-377 mimic on BCL-xL levels was validated at the protein level by western blot using an antibody against BCL-xL (Santa Cruz Biotechnology). 200 nM of miR-377 mimic (Qiagen), miR-377 inhibitor (Sigma), pMIG-Bcl-xL expression plasmid  (obtained from Addgene), siBCL-xL, or siControl (Santa Cruz Biotechnology) transfection in ABT-199R SU-DHL-6 cells was achieved using the Amaxa Nucleofector Kit V (Lonza, Walkersville, MD, USA) (program number O-007) according to the manufacturer’s protocol, as described earlier . siBCL-xL and siControl consist of pools of 3–5 target-specific 19–25 nt siRNAs. ABT-199R SU-DHL-6 cells were transfected with 1 μg of pMIG-Bcl-xL, followed 24 h later by transfection with 200 nM of miR-377 mimics. After an additional 24 h, BCL-xL expression levels were determined by quantitative RT-PCR.
The cell pellets were lysed with 1 % NP-40 lysis buffer (20 mmol/L Tris–HCl, pH 7.5; 1 mmol/L EDTA; 150 mmol/L NaCl; 1 % NP-40) phosphatase inhibitors cocktail 2 and 3 (Sigma) and containing protease inhibitors (Roche) for 30 to 45 min at 4 °C. Protein lysates were prepared after calculating protein concentration using the Bradford reagent (Biorad) and 50 μg of protein was resolved on 10 % SDS-PAGE followed by transferring to nitrocellulose (Millipore) . Immunoblotting was performed with primary antibodies against BCL-xL (Santa Cruz Biotechnology) and β-actin (Sigma). The secondary anti-mouse antibodies were purchased from Thermo-Fisher Scientific.
Purification of primary CLL cells and lymphocytes from healthy donors
Fluorescence in situ hybridization was used as part of the diagnostic evaluation of CLL patients . Peripheral blood samples from 76 patients with CLL and six healthy donors were obtained with the patients’ informed consent according to protocols approved by the Cleveland Clinic Institutional Review Board according to the Declaration of Helsinki. All primary CLL cells were freshly processed without freezing. Lymphocytes were purified by Ficoll-Paque PLUS (GE Healthcare) gradient centrifugation. A lymphocyte sample set isolated from 6 healthy donors was used to establish a baseline comparison between mRNA levels in CLL and healthy donors, with highly purified lymphocytes obtained using the Gambro Elutra Cell Separation System .
Cell death was assessed by phosphatidylserine externalization. Cell lines were stained with fluorescein-conjugated annexin V (BD Biosciences) and propidium iodide and analyzed on a BD FACSCalibur flow cytometer. Raw data were analyzed using the CellQuest Version 5.2.1 software. Results were normalized to survival of untreated cells. Flow cytometric immunophenotyping using fluorescently labeled monoclonal antibodies against ZAP70 and CD38 was performed at the Cleveland Clinic as part of diagnostic evaluation on a FACSCanto instrument (BD Biosciences). Staining protocols were standard lyses/washing protocols, as previously described .
RNA isolation and quantitative RT-PCR
Total RNA was isolated using the Trizol method (Invitrogen). 1 μg of RNA samples were reverse transcribed using the TaqMan reverse transcription kit and amplified using the SYBR Green Master Mix (Applied Biosystems) and examined on a 7500 Real-Time PCR system (Applied Biosystems). Quantitative, real-time reverse transcriptase polymerase chain reaction (RT-PCR) with the specific BCL-2 family primers was performed as we have described previously , using the respective primers for BCL-2 family and β-actin as a control. For the 5-aza-2’-deoxycytidine (5-Aza) experiment, RNA was isolated from ABT-199-resistant (ABT-199R) cell lines SU-DHL-6 and OCL-LY-19 treated with 5 μM 5-Aza (Sigma) for 72 h and expression determined by RT-PCR.
Megaplex™ RT Primers (Applied Biosystems), which are 380 stem-looped reverse transcripts that enable the synthesis of cDNA for mature miRNAs, were used. The TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) was used to make cDNAs for mature miRNAs. The SYBR Green Master Mix (Applied Biosystems) was used to amplify miR-377, using specific miR-377 primers  5’-GAGCAGAGGTTGCCCTTG-3’ (forward) and 5’-ACAAAAGTTGCCTTTGTGTGA-3’ (reverse). The U6 small nuclear RNA primers 5’-CTCGCTTCGGCAGCACA-3’ (forward) and 5’-AACGCTTCACGAATTTGCGT-3’ (reverse) were used as an internal control.
The Cox proportional hazards model was used to identify significant survival dependencies on covariates. To illustrate associations, Kaplan-Meier curves were plotted using covariates dichotomized at their medians and compared for significant differences using the log rank test. The Jonckheere-Terpstra test for trend was used to determine whether BCL-xL expression was related to increase in Rai stage. Two sample t-tests were used to compare advance tumor stages (stages III/IV) vs. early tumor stage (stages 0/I/II), BCL-xL expression in treated vs. untreated, ZAP70, CD38, and p53 (17p) status in CLL patients. The Spearman correlation was used to assess the strength and direction of association between BCL-xL and miR-377 expression. All computations were performed in R. P < 0.05 was used to indicate statistical significance. Patient records were extracted for dates of diagnosis and date of initiation of CLL-specific therapy in order to calculate time to progression to disease requiring treatment.
ABT-199-resistant cell lines
BCL-2 homology domain 3
cluster of differentiation 38
chronic lymphocytic leukemia
diffuse large B-cell lymphoma cells
germinal center B cells
- IGHV region:
immunoglobulin heavy chain variable region
tumor suppressor protein 53
reverse transcription polymerase chain reaction
small interfering RNA
zeta-chain-associated protein kinase 70
Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8(2):121–32.
Del Gaizo MV, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clinical Investig. 2007;117(1):112–21.
Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007;12(2):171–85.
Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621–32.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334(6059):1129–33.
Thomas A, Pepper C, Hoy T, Bentley P. Bcl-2 and bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients. Leuk Res. 2000;24(10):813–21.
Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood. 2008;112(9):3807–17.
Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 2007;13(7):2144–50.
Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012;30(25):3127–35.
Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood. 2011;118(13):3579–90.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.
Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, et al. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75(7):1366–75.
Garber K. Kinase inhibitors overachieve in CLL. Nat Rev Drug Discov. 2014;13(3):162–4.
Dalla-Favera R. Lymphoid malignancies: many tumor types, many altered genes, many therapeutic challenges. J Clinical Investig. 2012;122(10):3396–7.
Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood. 1987;69(3):929–36.
Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998;25(1):42–59.
Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804–15.
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893–901.
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–7.
Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 2009;23(1):25–47.
Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006;145(6):435–47.
Shindiapina P, Brown JR, Danilov AV. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. British J Haematol. 2014;167(2):149–61.
Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980–8.
Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329–36.
Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clinical Investig. 2013;123(6):2395–407.
Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15(6):546–54.
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nature reviews Clinical Oncol. 2011;8(8):467–77.
Bai M, Skyrlas A, Agnantis NJ, Kamina S, Tsanou E, Grepi C, et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Modern Pathol. 2004;17(7):847–56.
Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res. 2012;72(12):3069–79.
Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death & Disease. 2015;6:e1593.
Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Current Opinion Oncol. 2000;12(6):543–9.
Reindl L, Bacher U, Dicker F, Alpermann T, Kern W, Schnittger S, et al. Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms. British J Haematol. 2010;151(1):25–36.
Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66(15):7390–4.
Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle. 2007;6(12):1455–9.
Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2014;33(44):5173–82.
Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, et al. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res. 2014;20(12):3107–17.
Rossi D, Gaidano G. Richter syndrome. Advances Exp Med Biol. 2013;792:173–91.
Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2008;105(19):7004–9.
Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, Wen W, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012;33(5):1046–54.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.
Cosson A, Chapiro E, Belhouachi N, Cung HA, Keren B, Damm F, et al. 14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Genes, Chromosomes & Cancer. 2014;53(8):657–66.
Manodoro F, Marzec J, Chaplin T, Miraki-Moud F, Moravcsik E, Jovanovic JV, et al. Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood. 2014;123(13):2066–74.
Zehavi L, Schayek H, Jacob-Hirsch J, Sidi Y, Leibowitz-Amit R, Avni D. MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma. Mol Cancer. 2015;14:68.
Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10(3):176–82.
Amatori S, Bagaloni I, Donati B, Fanelli M. DNA demethylating antineoplastic strategies: a comparative point of view. Genes & cancer. 2010;1(3):197–209.
Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dpendency. Cancer Cell. 2012;21(4):547–62.
Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace Jr AJ. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 2000;60(21):6101–10.
Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25(7):799–804.
Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, et al. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. Cytometry B Clin Cytom. 2006;70(4):270–5.
Zhao WL, Daneshpouy ME, Mounier N, Briere J, Leboeuf C, Plassa LF, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood. 2004;103(2):695–7.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.
Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC. miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer. 2011;129(4):810–9.
Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8(3):705–11.
Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005;33(17):5394–403.
We would like to thank L. Rybicki for statistical expertise and Dr. C. Talerico (Cleveland Clinic) for providing substantive editing and comments. This work was supported by research grants from National Institutes of Health CA127264 to A. Almasan and CA154356 to A.H. Ting.
The authors declare that they have no competing interests.
SA and AA participated in designing the research. SA performed the research and data analysis. GC developed and characterized ABT-199-resistant cells. JE and GS designed and performed the luciferase reporter assay experiments. BH and MS contributed the patient samples and participated in their characterization. VN and AT designed, performed and interpreted 14q32 cluster methylation experiments. TR provided the statistical analysis. SA and AA wrote the paper, and all authors reviewed the final version of the manuscript.
BCL-XL mRNA structure. (A) The 3’-UTR mRNA of BCL-XL contains two predicted miR-377 binding sites. (B) The contextual/local secondary structures around the predicted miRNA target site in the short and full length 3’-UTR of Bcl-xL transcript as predicted by mFold and Nupack RNA folding algorithms. (JPEG 446 kb)
Lymphoid B-cell lines with low miR-377/high BCL-XL expression are more resistant to ABT-199. Cell viability of a panel of lymphoid B-cell lines after treatment with 200 nM of ABT-199. (JPEG 105 kb)
Kaplan-Meier curves for correlation of treatment-free survival with pro-apoptotic BCL-2 expression levels. (A) PUMA, (B) NOXA, and (C) BIM. P values shown are for the log-rank test. (JPEG 309 kb)
Correlation of BCL-XL expression and CLL prognostic markers. BCL-XL expression, as determined by quantitative RT-PCR, was plotted against (A) Rai stage, (B) p53 (17p), (C) ZAP70, and (D) CD38. Significance was determined by a t-test. (JPEG 281 kb)